How do we monitor asthma control?

Area of Science:

• Pulmonology
• Allergy and Immunology
• Respiratory Medicine

Background:

• Current asthma management relies on trigger avoidance, education, and action plans based on symptoms and lung function.
• Objective monitoring is crucial as patients and physicians may misjudge asthma symptom severity.
• The efficacy of symptom and peak flow monitoring in guiding therapy and achieving optimal asthma control remains debated.

Purpose of the Study:

• To evaluate the role of airway hyperresponsiveness (AHR) as a marker for guiding asthma management.
• To investigate if AHR-guided therapy improves clinical and histologic outcomes compared to standard approaches.
• To explore alternative, easily implementable markers for airway inflammation in routine asthma care.

Main Methods:

• Assessing airway hyperresponsiveness (AHR) as a noninvasive surrogate marker for airway inflammation.
• Tailoring inhaled corticosteroid dosage based on individual AHR levels.
• Comparing outcomes of AHR-guided therapy versus standard symptom and lung function-based management.

Main Results:

• Airway hyperresponsiveness (AHR) provides prognostic information on asthma control and serves as a valuable marker of airway inflammation.
• AHR-guided, limited increases in inhaled steroid dosage lead to better clinical and histologic outcomes.
• This tailored strategy optimizes treatment for individual patient needs, improving overall asthma control.

Conclusions:

• Monitoring airway hyperresponsiveness (AHR) offers a more personalized and effective approach to asthma management than symptom-based strategies alone.
• AHR-guided therapy can prevent airway remodeling and improve long-term asthma outcomes.
• Further research is needed to identify and validate easily implementable markers for routine asthma care.